Business context and reporting period
BioRestorative Therapies, Inc. filed this Form 10-K for the fiscal year ended December 31, 2023; it is an annual report, not a quarterly filing. The company develops cell- and tissue-based therapies and has not generated significant operating revenue. Its lead candidate, BRTX-100, is in a Phase 2 clinical trial for chronic lower back pain associated with degenerative disc disease. ThermoStem, a brown-fat cell therapy program for metabolic disorders, remains preclinical.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $145,800 | $119,800 |
| Research and development expense | $4,034,591 | $3,513,352 |
| General and administrative expense | $11,331,983 | $15,580,473 |
| Total operating expenses | $15,366,574 | $19,093,825 |
| Operating loss | $(15,220,774) | $(18,974,025) |
| Net loss | $(14,415,484) | $(18,494,769) |
| Net loss per share, basic and diluted | $(3.42) | $(5.11) |
| Net cash used in operations | $(6,430,211) | $(5,913,100) |
All reported revenue was royalty revenue under a sublicense agreement. The company reported no gross margin metric. Research and development expense rose 15%, while general and administrative expense fell 27%, mainly due to lower stock-based compensation. Net loss improved by about $4.1 million, helped by lower operating expenses and higher investment interest income ($552,293 versus $11,650).
At year-end, cash and cash equivalents plus marketable securities totaled $11,065,995; working capital was $10,327,134. Total assets were $12,611,720, total liabilities $1,063,392, and stockholders’ equity $11,548,328. Notes payable were zero; liabilities included $162,317 of current lease liability. Accumulated deficit was $167,056,381. The filing reports cash of $884,377 on the balance sheet but $886,947 at year-end in the cash flow statement.
Changes versus the prior year
- Revenue increased $26,000, remaining immaterial relative to operating expenses.
- R&D spending increased $521,239, including higher compensation and lab costs; lower CRO start-up costs partly offset the increase.
- G&A declined $4,248,490, largely reflecting a $4,753,377 reduction in stock-based compensation, partly offset by higher compensation.
- Operating cash use increased by about $517,000. Net loss was lower, but cash flow also reflected changes in non-cash items and working capital.
- In 2023, the company raised about $2.35 million net through an at-the-market program and a registered direct offering, and issued 817,860 shares through those financing transactions.
Outlook, risks and unusual items
Management expects continued operating losses and negative operating cash flows, with R&D and operating costs expected to rise. Management stated that year-end cash and investments, together with approximately $8.1 million of gross proceeds from February 2024 warrant exercises, should fund operations for at least 12 months after the financial statements’ issuance. The company says additional financing will be required for a contemplated Phase 3 BRTX-100 trial, ThermoStem development and general operations; it gives no assurance financing will be available on acceptable terms. It anticipates BRTX-100 commercialization will not be possible for at least five years.
The February 2024 warrant transaction generated approximately $8.1 million gross before fees. It involved reduced-price exercises, new five-year warrants for up to 2,513,686 shares at $2.43, and 1,351,580 paid-for shares held in abeyance due to a beneficial-ownership limit. The company paid Roth Capital approximately $528,000 plus expenses. These transactions create potential dilution. In 2023, the independent safety monitoring board recommended continuing the BRTX-100 Phase 2 study without protocol changes; the trial’s efficacy and safety outcomes remain uncertain.
Key risks include clinical-trial failure or delay, FDA approval uncertainty, limited commercial-scale manufacturing capacity, reliance on external suppliers and service providers, competition, reimbursement uncertainty, and the need for further capital. The company reported a material weakness in internal control over financial reporting and ineffective disclosure controls as of December 31, 2023. Remediation is ongoing. The financial statement auditor issued an unqualified opinion and reported no critical audit matters; the auditor did not opine on internal-control effectiveness. The company reported no legal proceedings and no off-balance-sheet arrangements material to investors.
Most important facts for investors to verify
- Clinical-trial status, enrollment and timing, and eventual Phase 2 efficacy and safety results for BRTX-100.
- Actual cash available after the February 2024 warrant exercise, associated fees, and remaining operating runway; reconcile the filing’s different year-end cash figures.
- Share-count and dilution effects from new warrants, shares held in abeyance, preferred stock, options and other potential issuances.
- Progress in remediating the disclosed material weakness in financial reporting controls.
- Funding needs and expected costs for a Phase 3 trial, ThermoStem studies and continuing operations.